[68Ga]Ga-FAPI-46 positron emission tomography for detection of lymph node metastasis in early rectal cancer (FARE Trial)

Amsterdam UMC0 个研究点目标入组 45 人开始时间: 2023年7月27日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Group A: Patients aged =18 years with suspected or confirmed cT1-3N0-1M0 rectal cancer, defined as tumour invasion not extending beyond the perirectal tissue on standard MRI, with or without evidence of locoregional LNM on MRI, and no evidence of distant metastases on chest and abdominal CT., Group A: Scheduled for primary TME (i.e. without prior local excision and without neo-adjuvant treatment)., Group A: Approval of the local multidisciplinary colorectal tumour board for performing primary TME., Group B: Patients aged =18 years with suspected or confirmed cT1-2N0M0 rectal cancer, defined as tumour invasion not beyond the muscularis propria on standard MRI, no evidence of LNM on MRI, and no evidence of distant metastases on chest and abdominal CT., Group B: Tumours with endoscopic features of deep submucosal/muscularis propria invasion defined as: NBI: Hiroshima C2/3, JNET 3, NICE III, or chromoendoscopy: Kudo Vn pit pattern and/or the presence of non-lifting in the presence of features of submucosal invasion (Hiroshima C1, JNET 2B, Kudo Vi pit pattern), thus a tumour suitable for local excision., Group B: Planned local excision using either EID or TAMIS., Group B: Approval of the local multidisciplinary colorectal tumour board for performing (diagnostic) local excision.

•Group A & B: Not able to communicate in Dutch or English, Group A & B: Neoadjuvant treatment (for current diagnosis of rectal cancer), Group A & B: Pregnant (either the patient or someone in the same household) or lactating women

发起方

Amsterdam UMC